Clarus Therapeutics withdraws IPO

Clarus Therapeutics, a biotech with an oral testosterone replacement therapy entering Phase 3, withdrew its plans for an initial public offering on Friday, citing poor market conditions. 

The Northbrook, IL-based company was founded in 2003. Piper Jaffray, Wells Fargo Securities were set to be the lead underwriters on the deal.